Aijaz Ahmed, MD
Gastroenterology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 2 carriers
- Offices
- 9
Offices
9 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: French Hospital Medical Center · Marian Regional Medical Center · Renown Regional Medical Center · Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
13 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Ahmed’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
13 of 13 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A60520 · Current
Licensed to practise in California · since 1996 · expires 2028-05-31 · University of Karachi, Dow Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
5 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- French Hospital Medical CenterSan Luis Obispo, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 3 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.23, Oct 2024 – Sep 2025
- Marian Regional Medical CenterSanta Maria, CAAcute Care Hospital · Voluntary non-profit - Church · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 3 of 5 · 68% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 0.67 (0.37 to 0.96), Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.081, Oct 2024 – Sep 2025
- Renown Regional Medical CenterReno, NVAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Renown Health, which runs 3 hospitalsPatients rate it 3 of 5 · 69% would definitely recommend itOverall rating: 3 of 5 starsWorse than the national rate — Death rate among surgical inpatients with serious treatable complications: 231.33 (200.05 to 262.61) · 302 cases, Jul 2022 – Jun 2024Better than the national rate — Pressure ulcer rate: 0.14 (0 to 0.56) · 11,907 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.438, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.208, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.636, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.344, Oct 2024 – Sep 2025Better than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 7.9 (6.3 to 9.9) · 547 cases, Jan 2024 – Dec 2024
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for French Hospital Medical Center
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.23 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.89 (0 to 1.89) · 660 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.71 (0.39 to 1.04) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 154.33 (99.56 to 209.1) · 63 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 78 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.9 · 56 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.3 · 273 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 13.7 · 355 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 275 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.5 · 69 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 1,569 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 4,085 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.07 to 0.47) · 4,358 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.69 (0.53 to 4.85) · 1,221 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.97 (0.47 to 3.48) · 567 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.54 (1.03 to 4.05) · 1,101 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.3 (0.36 to 12.23) · 585 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 3.66 (0.03 to 7.29) · 576 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.98 (0.5 to 3.47) · 185 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.2 (0 to 0.96) · 3,231 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.2 · 53 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 2.935 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.6 · 252 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 330 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -2.9 · 296 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -8.5 · 382 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 2 · 272 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.9 · 248 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.1 (3.2 to 8) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.7 (6.5 to 14.1) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.5 · 40 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10 · 77 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.7 (8.9 to 15.1) · 837 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 706 cases | No different | Jan 2024 – Dec 2024 |
What patients said (706 patients answered, 28% of those asked)
| Cleanliness | 3 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 5 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 90% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 77% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 33% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 91% |
See every measure and the patient survey for Marian Regional Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 1 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 1 better, 8 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.67 (0.37 to 0.96) | Better | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.081 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.99 (0.06 to 1.93) · 1,191 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 189.73 (139.29 to 240.17) · 66 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.7 · 103 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.8 · 161 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 15.9 · 247 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.7 · 478 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.4 · 470 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.5 · 237 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.5 · 3,050 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.14 (0 to 0.34) · 8,823 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.05 to 0.42) · 8,672 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.87 (0.97 to 4.76) · 2,024 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.12 (0.57 to 3.67) · 782 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.29 (0.85 to 3.72) · 1,934 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 3.63 (0 to 9.97) · 787 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.01 (1.37 to 8.65) · 748 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.88 (0.43 to 3.32) · 373 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.13 (0 to 0.73) · 6,968 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 179 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.245 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.85 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.952 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.687 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.5 · 198 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.6 · 469 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 18.8 · 232 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.8 · 541 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -8.6 · 473 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 434 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.6 (5 to 8.4) · 519 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.9 (8.8 to 13.4) · 519 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.2 · 152 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.3 · 83 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.2 to 17) · 124 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.9 to 1.4) · 638 cases | No different | Jan 2024 – Dec 2024 |
What patients said (666 patients answered, 17% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 64% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 79% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 68% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
See every measure and the patient survey for Renown Regional Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 1 worse of 8 measures. Safety: 3 better, 4 the same, 0 worse of 7 measures. Readmissions: 1 better, 9 the same, 0 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 231.33 (200.05 to 262.61) · 302 cases | Worse | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.56) · 11,907 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.438 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.208 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.636 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.344 | Better | Oct 2024 – Sep 2025 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 7.9 (6.3 to 9.9) · 547 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.14 (0.36 to 1.92) · 3,106 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.04 (0.81 to 1.27) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.3 · 123 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 225 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11 · 592 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 12.9 · 734 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.4 · 585 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11 · 683 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 6,021 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.27 (0.11 to 0.44) · 14,463 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.33 (0.16 to 0.5) · 14,984 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.71 (3.29 to 6.12) · 4,503 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.62 (1.22 to 4.02) · 1,605 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 3.24 (2.11 to 4.36) · 4,125 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.78 (7 to 16.56) · 1,560 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (2.2 to 8.2) · 1,551 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.53 (0.22 to 2.83) · 1,024 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.531 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.725 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 12.9 · 668 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.2 · 1,041 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -11.3 · 643 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 1.6 · 850 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -8.5 · 631 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.3 · 776 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.8 (3.6 to 6.5) · 547 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 10 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.1 · 354 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.3 (9.8 to 18.1) · 50 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.3) · 948 cases | No different | Jan 2024 – Dec 2024 |
What patients said (849 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 72% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 80% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 71% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 44% |
| "YES", patients would definitely recommend the hospital | 69% |
| Staff "always" explained possible side effects | 41% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$87,063
Medicare paid this office $87,063 for 480 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 226 | $28,331 | $97 |
| Long return visit (40+ min) | 116 | $20,847 | $153 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 43 | $17,284 | $106 |
| Telephone medical discussion with physician, 21-30 minutes | 52 | $6,373 | $97 |
| New patient visit (45+ min) | 47 | $6,053 | $129 |
See all 8 services
| Return visit (30+ min) | 226 | $28,331 | $97 |
| Long return visit (40+ min) | 116 | $20,847 | $153 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 43 | $17,284 | $106 |
| Telephone medical discussion with physician, 21-30 minutes | 52 | $6,373 | $97 |
| New patient visit (45+ min) | 47 | $6,053 | $129 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 18 | $2,104 | $117 |
| Hospital discharge day management, more than 30 minutes | 15 | $1,460 | $97 |
| Measurement of liver stiffness | 25 | $258 | $10 |
Procedures Medicare counted
| Colonoscopy | 1-10 | None |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 1-10 | None |
Who their Medicare patients are
480 Original Medicare patients in 2024. Average age 71 · Under 65 11% · 85 and older 4% · Women 53% · Also on Medicaid 28% · Health risk score 2.17. Above the middle of the specialty; the typical gastroenterology clinician is at 1.42.
Conditions among them: High blood pressure 75% · Diabetes 41% · Chronic kidney disease 36% · Coronary heart disease 25% · Depression 21% · Heart failure 16% · Cancer 14% · Atrial fibrillation 14% · COPD 11% · Dementia 8% · Stroke 7%.
The office billed $435,929, Medicare allowed $117,281 and paid $87,063; for 797 services of 17 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 480 | 797 | 71 | 2.17 | $435,929 | $87,063 |
| 2023 | 569 | 1,275 | 71 | 2.22 | $563,342 | $105,825 |
| 2022 | 536 | 1,053 | 70 | 2.07 | $492,830 | $93,350 |
| 2021 | 534 | 1,130 | 70 | 2.19 | $434,032 | $88,511 |
| 2020 | 574 | 1,188 | 69 | 2.19 | $530,361 | $92,777 |
| 2019 | 580 | 1,089 | 68 | 2.21 | $606,928 | $104,850 |
| 2018 | 595 | 1,103 | 67 | 2.20 | $584,894 | $102,551 |
| 2017 | 650 | 1,392 | 67 | 2.27 | $604,208 | $124,179 |
| 2016 | 640 | 1,473 | 66 | 2.34 | $596,375 | $137,560 |
| 2015 | 496 | 1,194 | 66 | 2.57 | $449,977 | $106,552 |
| 2014 | 379 | 1,128 | 66 | 2.43 | $365,331 | $96,121 |
| 2013 | 385 | 883 | 65 | 2.38 | $295,425 | $74,467 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 15 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 65 | $29,071 | $110 |
| Return visit (30+ min) | 224 | $25,803 | $93 |
| Telephone medical discussion with physician, 21-30 minutes | 86 | $9,669 | $105 |
| New patient visit (45+ min) | 53 | $6,166 | $116 |
| Telehealth originating site facility fee | 220 | $5,778 | $21 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 33 | $5,438 | $160 |
| Long return visit (40+ min) | 35 | $4,089 | $102 |
| Hospital discharge day management, more than 30 minutes | 29 | $3,534 | $107 |
| Return visit (30+ min) | 31 | $2,800 | $90 |
| Long return visit (40+ min) | 28 | $2,556 | $80 |
| Short return visit (20+ min) | 43 | $2,008 | $46 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $1,674 | $120 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 13 | $1,419 | $101 |
| Short return visit | 16 | $251 | $16 |
| Measurement of liver stiffness | 13 | $126 | $10 |
2022: 13 services
| Long return visit (40+ min) | 143 | $21,039 | $132 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 53 | $20,033 | $91 |
| Return visit (30+ min) | 109 | $9,466 | $85 |
| Short return visit (20+ min) | 117 | $8,720 | $64 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 39 | $7,426 | $181 |
| Long return visit (40+ min) | 47 | $6,639 | $116 |
| New patient visit (45+ min) | 33 | $4,106 | $124 |
| Telephone medical discussion with physician, 21-30 minutes | 41 | $4,091 | $91 |
| Telehealth originating site facility fee | 122 | $3,155 | $20 |
| Hospital discharge day management, more than 30 minutes | 15 | $1,668 | $98 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 13 | $1,254 | $96 |
| Telephone medical discussion with physician, 21-30 minutes | 11 | $906 | $70 |
| Measurement of liver stiffness | 18 | $174 | $10 |
2021: 11 services
| Return visit (30+ min) | 214 | $24,946 | $89 |
| Telephone medical discussion with physician, 21-30 minutes | 146 | $15,325 | $91 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 43 | $13,364 | $95 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 33 | $6,661 | $185 |
| New patient visit (45+ min) | 47 | $6,004 | $128 |
| Telehealth originating site facility fee | 216 | $5,319 | $20 |
| Return visit (30+ min) | 36 | $4,045 | $83 |
| Short return visit (20+ min) | 53 | $3,707 | $70 |
| Telephone medical discussion with physician, 21-30 minutes | 22 | $2,514 | $90 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 14 | $1,560 | $111 |
| Hospital discharge day management, more than 30 minutes | 13 | $1,401 | $100 |
2020: 12 services
| Return visit (30+ min) | 232 | $20,984 | $71 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 58 | $18,239 | $97 |
| Telephone medical discussion with physician, 21-30 minutes | 144 | $13,267 | $81 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 40 | $8,273 | $188 |
| New patient visit (45+ min) | 72 | $8,187 | $114 |
| Long return visit (40+ min) | 58 | $6,734 | $105 |
| Telehealth originating site facility fee | 183 | $4,823 | $21 |
| Long return visit (40+ min) | 23 | $2,199 | $92 |
| Telephone medical discussion with physician, 21-30 minutes | 20 | $1,479 | $70 |
| Return visit (30+ min) | 19 | $1,438 | $72 |
| Hospital discharge day management, more than 30 minutes | 12 | $1,313 | $101 |
| Telephone medical discussion with physician, 11-20 minutes | 11 | $592 | $54 |
2019: 7 services
| Return visit (30+ min) | 279 | $29,188 | $79 |
| Long return visit (40+ min) | 150 | $23,237 | $104 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 60 | $19,900 | $94 |
| New patient visit (45+ min) | 91 | $10,564 | $116 |
| Long return visit (40+ min) | 66 | $9,885 | $92 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 32 | $6,057 | $184 |
| New patient visit (60+ min) | 13 | $1,812 | $139 |
2018: 10 services
| Return visit (30+ min) | 256 | $24,993 | $76 |
| Long return visit (40+ min) | 126 | $19,020 | $109 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 50 | $18,905 | $94 |
| New patient visit (45+ min) | 81 | $9,408 | $116 |
| Long return visit (40+ min) | 51 | $7,040 | $98 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 33 | $6,911 | $182 |
| Return visit (30+ min) | 95 | $5,987 | $56 |
| Hospital discharge day management, more than 30 minutes | 16 | $1,778 | $99 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 18 | $1,574 | $87 |
| New patient visit (45+ min) | 13 | $1,309 | $101 |
2017: 11 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 64 | $28,913 | $92 |
| Return visit (30+ min) | 221 | $24,644 | $78 |
| Long return visit (40+ min) | 136 | $22,456 | $103 |
| Return visit (30+ min) | 162 | $15,539 | $62 |
| New patient visit (45+ min) | 81 | $9,725 | $120 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 25 | $5,076 | $181 |
| New patient visit (45+ min) | 31 | $3,453 | $111 |
| Long return visit (40+ min) | 20 | $2,690 | $100 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 24 | $2,392 | $92 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 16 | $1,953 | $122 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 27 | $125 | $5 |
2016: 11 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 89 | $37,452 | $92 |
| Return visit (30+ min) | 221 | $25,520 | $82 |
| Return visit (30+ min) | 179 | $18,548 | $63 |
| Long return visit (40+ min) | 121 | $18,049 | $111 |
| New patient visit (45+ min) | 82 | $10,505 | $128 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 31 | $6,670 | $176 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 28 | $3,540 | $111 |
| Hospital discharge day management, more than 30 minutes | 31 | $3,530 | $95 |
| New patient visit (45+ min) | 21 | $2,192 | $104 |
| Long return visit (40+ min) | 23 | $2,081 | $83 |
| New patient visit (60+ min) | 13 | $2,009 | $155 |
2015: 9 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 75 | $30,483 | $93 |
| Return visit (30+ min) | 214 | $27,099 | $66 |
| Return visit (30+ min) | 165 | $21,136 | $85 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 32 | $5,733 | $179 |
| New patient visit (45+ min) | 39 | $5,082 | $130 |
| New patient visit (45+ min) | 40 | $4,495 | $112 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 21 | $2,310 | $110 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 16 | $1,860 | $116 |
| Hospital discharge day management, more than 30 minutes | 17 | $1,760 | $98 |
2014: 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 81 | $37,130 | $92 |
| Return visit (30+ min) | 204 | $30,818 | $66 |
| Return visit (30+ min) | 56 | $6,544 | $81 |
| New patient visit (45+ min) | 46 | $5,171 | $112 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $4,856 | $180 |
| Hospital discharge day management, more than 30 minutes | 17 | $2,317 | $97 |
| New patient visit (45+ min) | 19 | $2,246 | $118 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 18 | $2,207 | $110 |
2013: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 84 | $27,562 | $90 |
| Return visit (30+ min) | 203 | $23,078 | $62 |
| New patient visit (45+ min) | 56 | $6,030 | $108 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 27 | $4,902 | $175 |
| Return visit (30+ min) | 34 | $3,456 | $84 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 26 | $3,182 | $118 |
Medicaid work
$14,086 in 2024
Medicaid paid $14,086 for 247 billed services this clinician did in 2024, up to 26 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 137 | $10,717 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 110 | $3,369 |
| 2024 | 247 | 2 | 26 | $14,086 |
| 2023 | 654 | 4 | 36 | $25,155 |
| 2022 | 558 | 2 | 33 | $24,413 |
| 2021 | 336 | 2 | 22 | $13,988 |
| 2020 | 175 | 4 | 19 | $7,235 |
| 2019 | 127 | 3 | 17 | $5,229 |
| 2018 | 117 | 2 | 15 | $6,205 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 315 | $12,118 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 301 | $11,781 |
| Hospital inpatient or observation discharge day management; more than 30 minutes on the date of the encounter | 26 | $1,206 |
| Telehealth originating site facility fee | 12 | $51 |
2022
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 403 | $18,561 |
| Return visit (30+ min) | 155 | $5,852 |
2021
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 181 | $9,036 |
| Return visit (30+ min) | 155 | $4,952 |
2020
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 127 | $5,768 |
| Long return visit (40+ min) | 14 | $828 |
| Return visit (30+ min) | 20 | $498 |
| Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous 7 days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 21-30 minutes of medical discussion | 14 | $141 |
2019
| Long return visit (40+ min) | 63 | $3,058 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 32 | $1,091 |
| Return visit (30+ min) | 32 | $1,080 |
2018
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 74 | $4,945 |
| Return visit (30+ min) | 43 | $1,260 |
Drugs they prescribed that Part D paid
$452,877
Pharmacies billed $452,877 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,381) in 2024. At or below the middle of the specialty; the typical gastroenterology clinician is at 0%.
1,170 generic and 211 brand-name prescriptions · $452,877 in drug cost · 24 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Vemlidy | 123 | $177,869 | $1,446 |
| Xifaxan | 20 | $71,678 | $3,584 |
| Tacrolimus | 211 | $38,185 | $181 |
| Entecavir | 83 | $28,661 | $345 |
| Ursodiol | 150 | $26,059 | $174 |
See all 29 drugs
| Vemlidy | 123 | $177,869 | $1,446 |
| Xifaxan | 20 | $71,678 | $3,584 |
| Tacrolimus | 211 | $38,185 | $181 |
| Entecavir | 83 | $28,661 | $345 |
| Ursodiol | 150 | $26,059 | $174 |
| Mycophenolate Mofetil | 89 | $15,120 | $170 |
| Eliquis | 23 | $13,415 | $583 |
| Sirolimus | 19 | $11,873 | $625 |
| Azathioprine | 37 | $2,225 | $60 |
| Fluconazole | 14 | $1,291 | $92 |
| Tenofovir Disoproxil | 29 | $1,252 | $43 |
| Fludrocortisone Acetate | 40 | $1,140 | $28 |
| Colchicine | 12 | $744 | $62 |
| Prevalite | 12 | $638 | $53 |
| Omeprazole | 25 | $609 | $24 |
| Pantoprazole | 72 | $546 | $8 |
| Prednisone | 71 | $487 | $7 |
| Gabapentin | 16 | $163 | $10 |
| Tamsulosin | 31 | $153 | $5 |
| Amiloride | 11 | $138 | $13 |
| Amlodipine Besylate | 31 | $112 | $4 |
| Furosemide | 25 | $80 | $3 |
| Calcitriol | 12 | $68 | $6 |
| Amitriptyline | 12 | $39 | $3 |
| Trazodone | 21 | $35 | $2 |
| Carvedilol | 16 | $34 | $2 |
| Metoprolol | 21 | $33 | $2 |
| Famotidine | 16 | $25 | $2 |
| Alendronate | 11 | $19 | $2 |
Year by year
| 2024 | 1,381 | 156 | 0% (0) | 15% | $452,877 |
| 2023 | 1,135 | 142 | 0% (0) | 14% | $462,656 |
| 2022 | 1,105 | 130 | 0% (0) | None | $594,632 |
| 2021 | 1,307 | 178 | 0% (0) | 25% | $1,094,881 |
| 2020 | 1,664 | 195 | 0% (0) | 27% | $1,080,548 |
| 2019 | 1,713 | 191 | None | 27% | $1,497,760 |
| 2018 | 2,067 | 229 | None | None | $2,080,971 |
| 2017 | 2,391 | 264 | None | 29% | $3,760,620 |
| 2016 | 2,738 | 274 | 1% (13) | None | $5,366,420 |
| 2015 | 3,219 | 347 | 0% (14) | None | $12,703,034 |
| 2014 | 2,723 | 293 | 1% (23) | None | $9,680,915 |
| 2013 | 1,706 | 228 | 1% (12) | None | $738,052 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 24 drugs
| Vemlidy | 95 | $155,126 | $1,633 |
| Tacrolimus | 213 | $36,825 | $173 |
| Entecavir | 85 | $34,393 | $405 |
| Ursodiol | 104 | $23,450 | $225 |
| Valganciclovir | 17 | $20,889 | $1,229 |
| Sirolimus | 13 | $19,402 | $1,492 |
| Baraclude | 13 | $19,273 | $1,483 |
| Mycophenolate Mofetil | 85 | $7,966 | $94 |
| Azathioprine | 31 | $3,431 | $111 |
| Prevalite | 13 | $1,607 | $124 |
| Colchicine | 13 | $1,207 | $93 |
| Pantoprazole | 62 | $1,106 | $18 |
| Lactulose | 14 | $1,068 | $76 |
| Tenofovir Disoproxil | 25 | $922 | $37 |
| Fludrocortisone Acetate | 26 | $796 | $31 |
| Nystatin | 13 | $631 | $49 |
| Prednisone | 45 | $492 | $11 |
| Omeprazole | 30 | $486 | $16 |
| Peg 3350-Electrolyte | 14 | $305 | $22 |
| Amlodipine Besylate | 16 | $203 | $13 |
| Trazodone | 13 | $135 | $10 |
| Tamsulosin | 15 | $125 | $8 |
| Furosemide | 16 | $101 | $6 |
| Metoprolol | 14 | $33 | $2 |
2022: 24 drugs
| Vemlidy | 77 | $107,673 | $1,398 |
| Xifaxan | 23 | $92,124 | $4,005 |
| Ursodiol | 97 | $44,621 | $460 |
| Tacrolimus | 244 | $42,877 | $176 |
| Baraclude | 17 | $25,076 | $1,475 |
| Enoxaparin | 16 | $14,985 | $937 |
| Entecavir | 66 | $14,906 | $226 |
| Sirolimus | 19 | $14,710 | $774 |
| Mycophenolate Mofetil | 108 | $9,626 | $89 |
| Mycophenolic Acid | 14 | $5,791 | $414 |
| Azathioprine | 20 | $2,285 | $114 |
| Lactulose | 13 | $2,098 | $161 |
| Colchicine | 13 | $1,413 | $109 |
| Lamivudine Hbv | 12 | $1,235 | $103 |
| Pantoprazole | 78 | $1,043 | $13 |
| Tenofovir Disoproxil | 22 | $905 | $41 |
| Fludrocortisone Acetate | 13 | $367 | $28 |
| Prednisone | 31 | $316 | $10 |
| Amlodipine Besylate | 20 | $266 | $13 |
| Gabapentin | 13 | $241 | $19 |
| Peg 3350-Electrolyte | 15 | $239 | $16 |
| Tamsulosin | 13 | $233 | $18 |
| Levothyroxine | 13 | $176 | $14 |
| Furosemide | 12 | $61 | $5 |
2021: 24 drugs
| Epclusa | 12 | $316,835 | $26,403 |
| Vemlidy | 167 | $216,388 | $1,296 |
| Mavyret | 13 | $180,247 | $13,865 |
| Xifaxan | 59 | $170,609 | $2,892 |
| Baraclude | 29 | $40,746 | $1,405 |
| Tacrolimus | 219 | $27,771 | $127 |
| Ursodiol | 100 | $25,889 | $259 |
| Valganciclovir | 29 | $7,909 | $273 |
| Mycophenolate Mofetil | 63 | $7,254 | $115 |
| Entecavir | 58 | $6,518 | $112 |
| Lactulose | 28 | $2,169 | $77 |
| Azathioprine | 46 | $1,741 | $38 |
| Tenofovir Disoproxil | 26 | $1,225 | $47 |
| Pantoprazole | 66 | $1,082 | $16 |
| Fluconazole | 15 | $794 | $53 |
| Spironolactone | 24 | $645 | $27 |
| Prednisone | 64 | $495 | $8 |
| Omeprazole | 17 | $428 | $25 |
| Fenofibrate | 12 | $381 | $32 |
| Fludrocortisone Acetate | 11 | $254 | $23 |
| Amlodipine Besylate | 27 | $249 | $9 |
| Tamsulosin | 23 | $248 | $11 |
| Levothyroxine | 13 | $168 | $13 |
| Furosemide | 27 | $121 | $4 |
2020: 29 drugs
| Vemlidy | 207 | $249,557 | $1,206 |
| Xifaxan | 79 | $205,563 | $2,602 |
| Mavyret | 14 | $186,379 | $13,313 |
| Tacrolimus | 282 | $50,947 | $181 |
| Baraclude | 32 | $44,515 | $1,391 |
| Ursodiol | 113 | $37,590 | $333 |
| Entecavir | 92 | $27,493 | $299 |
| Atovaquone | 11 | $10,188 | $926 |
| Sirolimus | 12 | $8,542 | $712 |
| Mycophenolate Mofetil | 82 | $8,481 | $103 |
| Tenofovir Disoproxil | 44 | $8,384 | $191 |
| Valganciclovir | 21 | $6,808 | $324 |
| Colchicine | 13 | $3,659 | $281 |
| Lactulose | 41 | $3,356 | $82 |
| Azathioprine | 63 | $2,528 | $40 |
| Fluconazole | 12 | $1,359 | $113 |
| Pantoprazole | 79 | $940 | $12 |
| Spironolactone | 23 | $533 | $23 |
| Omeprazole | 31 | $529 | $17 |
| Prednisone | 62 | $486 | $8 |
| Fludrocortisone Acetate | 15 | $331 | $22 |
| Furosemide | 45 | $304 | $7 |
| Amiloride | 12 | $291 | $24 |
| Amlodipine Besylate | 35 | $236 | $7 |
| Constulose | 11 | $234 | $21 |
| Tamsulosin | 37 | $183 | $5 |
| Atorvastatin | 16 | $90 | $6 |
| Gabapentin | 14 | $89 | $6 |
| Metoprolol | 21 | $76 | $4 |
2019: 30 drugs
| Mavyret | 25 | $340,096 | $13,604 |
| Xifaxan | 108 | $266,559 | $2,468 |
| Vemlidy | 116 | $132,401 | $1,141 |
| Baraclude | 38 | $52,474 | $1,381 |
| Ursodiol | 127 | $48,816 | $384 |
| Sandostatin Lar Depot | 11 | $47,696 | $4,336 |
| Tacrolimus | 294 | $43,566 | $148 |
| Entecavir | 111 | $24,862 | $224 |
| Viread | 16 | $18,196 | $1,137 |
| Tenofovir Disoproxil | 51 | $15,984 | $313 |
| Mycophenolate Mofetil | 135 | $9,707 | $72 |
| Mycophenolic Acid | 16 | $8,587 | $537 |
| Prograf | 13 | $7,138 | $549 |
| Colchicine | 13 | $4,612 | $355 |
| Lamivudine Hbv | 16 | $3,323 | $208 |
| Azathioprine | 50 | $2,891 | $58 |
| Lactulose | 36 | $1,921 | $53 |
| Pantoprazole | 60 | $785 | $13 |
| Omeprazole | 50 | $756 | $15 |
| Constulose | 18 | $520 | $29 |
| Spironolactone | 35 | $405 | $12 |
| Amiloride | 16 | $377 | $24 |
| Fludrocortisone Acetate | 16 | $351 | $22 |
| Nifedipine Er | 12 | $282 | $24 |
| Prednisone | 28 | $247 | $9 |
| Furosemide | 29 | $134 | $5 |
| Tamsulosin | 12 | $94 | $8 |
| Amlodipine Besylate | 27 | $91 | $3 |
| Levothyroxine | 14 | $69 | $5 |
| Metoprolol | 12 | $32 | $3 |
2018: 36 drugs
| Epclusa | 19 | $469,214 | $24,695 |
| Harvoni | 14 | $437,396 | $31,243 |
| Xifaxan | 97 | $229,763 | $2,369 |
| Mavyret | 11 | $144,594 | $13,145 |
| Baraclude | 66 | $100,789 | $1,527 |
| Entecavir | 178 | $95,150 | $535 |
| Vemlidy | 86 | $92,122 | $1,071 |
| Tacrolimus | 385 | $54,576 | $142 |
| Viread | 49 | $52,511 | $1,072 |
| Ursodiol | 114 | $51,788 | $454 |
| Tenofovir Disoproxil | 74 | $47,180 | $638 |
| Sandostatin Lar Depot | 11 | $45,565 | $4,142 |
| Mycophenolate Mofetil | 188 | $14,972 | $80 |
| Lamivudine Hbv | 22 | $9,194 | $418 |
| Prograf | 11 | $5,988 | $544 |
| Colchicine | 13 | $4,706 | $362 |
| Gengraf | 24 | $4,546 | $189 |
| Lactulose | 69 | $2,799 | $41 |
| Azathioprine | 40 | $2,202 | $55 |
| Midodrine | 16 | $1,692 | $106 |
| Fluconazole | 13 | $1,312 | $101 |
| Constulose | 26 | $797 | $31 |
| Amiloride | 13 | $678 | $52 |
| Omeprazole | 51 | $636 | $12 |
| Spironolactone | 51 | $604 | $12 |
| Pantoprazole | 23 | $398 | $17 |
| Amitriptyline | 11 | $385 | $35 |
| Oxybutynin Chloride Er | 12 | $324 | $27 |
| Prednisone | 33 | $319 | $10 |
| Generlac | 11 | $311 | $28 |
| Levothyroxine | 15 | $211 | $14 |
| Potassium Chloride | 12 | $211 | $18 |
| Atorvastatin | 13 | $202 | $16 |
| Amlodipine Besylate | 23 | $170 | $7 |
| Furosemide | 44 | $110 | $2 |
| Metoprolol | 25 | $85 | $3 |
2017: 39 drugs
| Harvoni | 42 | $1,338,483 | $31,869 |
| Epclusa | 39 | $987,387 | $25,318 |
| Xifaxan | 97 | $215,374 | $2,220 |
| Zepatier | 11 | $203,969 | $18,543 |
| Viread | 141 | $158,135 | $1,122 |
| Entecavir | 172 | $104,348 | $607 |
| Baraclude | 60 | $83,258 | $1,388 |
| Tacrolimus | 404 | $54,712 | $135 |
| Vemlidy | 54 | $53,805 | $996 |
| Ursodiol | 127 | $48,694 | $383 |
| Lamivudine Hbv | 31 | $13,537 | $437 |
| Prograf | 32 | $13,034 | $407 |
| Mycophenolate Mofetil | 177 | $11,551 | $65 |
| Mycophenolic Acid | 15 | $7,126 | $475 |
| Nexium | 13 | $6,239 | $480 |
| Epivir Hbv | 12 | $5,839 | $487 |
| Gengraf | 28 | $5,042 | $180 |
| Colchicine | 14 | $4,685 | $335 |
| Azathioprine | 41 | $3,346 | $82 |
| Creon | 13 | $3,209 | $247 |
| Epivir | 14 | $2,916 | $208 |
| Dexilant | 11 | $2,817 | $256 |
| Lactulose | 53 | $2,057 | $39 |
| Fluconazole | 16 | $1,399 | $87 |
| Spironolactone | 65 | $885 | $14 |
| Omeprazole | 71 | $711 | $10 |
| Pantoprazole | 54 | $605 | $11 |
| Prednisone | 54 | $456 | $8 |
| Levothyroxine | 21 | $317 | $15 |
| Propranolol | 18 | $275 | $15 |
| Amlodipine Besylate | 51 | $227 | $4 |
| Furosemide | 45 | $222 | $5 |
| Atorvastatin | 17 | $189 | $11 |
| Constulose | 11 | $154 | $14 |
| Tamsulosin | 11 | $138 | $13 |
| Metoprolol | 30 | $119 | $4 |
| Nifedipine Er | 13 | $106 | $8 |
| Famotidine | 14 | $60 | $4 |
| Alendronate | 16 | $43 | $3 |
2016: 49 drugs
| Harvoni | 82 | $2,589,993 | $31,585 |
| Epclusa | 47 | $1,175,004 | $25,000 |
| Sovaldi | 16 | $452,884 | $28,305 |
| Viread | 154 | $157,019 | $1,020 |
| Xifaxan | 77 | $155,513 | $2,020 |
| Entecavir | 168 | $144,680 | $861 |
| Baraclude | 95 | $122,916 | $1,294 |
| Ursodiol | 173 | $60,995 | $353 |
| Tacrolimus | 392 | $54,592 | $139 |
| Sirolimus | 29 | $23,190 | $800 |
| Atovaquone | 12 | $17,055 | $1,421 |
| Prograf | 39 | $14,986 | $384 |
| Lamivudine Hbv | 31 | $13,909 | $449 |
| Mycophenolate Mofetil | 162 | $8,774 | $54 |
| Mycophenolic Acid | 15 | $7,676 | $512 |
| Sandimmune | 14 | $7,027 | $502 |
| Epivir Hbv | 13 | $5,897 | $454 |
| Januvia | 15 | $5,535 | $369 |
| Colcrys | 13 | $5,132 | $395 |
| Gengraf | 18 | $3,127 | $174 |
| Ribasphere | 20 | $2,904 | $145 |
| Creon | 12 | $2,843 | $237 |
| Azathioprine | 57 | $2,834 | $50 |
| Epivir | 13 | $2,714 | $209 |
| Omega-3 Acid Ethyl Esters | 13 | $1,934 | $149 |
| Fluconazole | 12 | $1,849 | $154 |
| Lactulose | 33 | $1,488 | $45 |
| Omeprazole | 143 | $1,060 | $7 |
| Spironolactone | 59 | $1,001 | $17 |
| Generlac | 17 | $746 | $44 |
| Pantoprazole | 61 | $743 | $12 |
| Prednisone | 73 | $707 | $10 |
| Constulose | 19 | $478 | $25 |
| Propranolol | 20 | $475 | $24 |
| Amlodipine Besylate | 70 | $304 | $4 |
| Tamsulosin | 21 | $304 | $14 |
| Glipizide | 36 | $295 | $8 |
| Citalopram Hbr | 20 | $290 | $14 |
| Fludrocortisone Acetate | 24 | $280 | $12 |
| Levothyroxine | 22 | $241 | $11 |
| Metoprolol | 46 | $236 | $5 |
| Furosemide | 50 | $230 | $5 |
| Potassium Chloride | 14 | $201 | $14 |
| Tramadol | 13 | $200 | $15 |
| Trazodone | 15 | $131 | $9 |
| Alendronate | 14 | $67 | $5 |
| Famotidine | 16 | $65 | $4 |
| Metformin | 15 | $42 | $3 |
| Hydrochlorothiazide | 12 | $15 | $1 |
2015: 43 drugs
| Harvoni | 291 | $9,190,382 | $31,582 |
| Sovaldi | 78 | $2,160,107 | $27,694 |
| Baraclude | 198 | $231,161 | $1,167 |
| Xifaxan | 109 | $167,030 | $1,532 |
| Viread | 149 | $148,709 | $998 |
| Entecavir | 124 | $116,233 | $937 |
| Ursodiol | 193 | $76,923 | $399 |
| Tacrolimus | 439 | $61,059 | $139 |
| Atovaquone | 17 | $23,850 | $1,403 |
| Prograf | 51 | $20,795 | $408 |
| Cellcept | 19 | $16,435 | $865 |
| Mycophenolate Mofetil | 173 | $9,089 | $53 |
| Ribasphere | 54 | $8,160 | $151 |
| Lamivudine Hbv | 20 | $6,715 | $336 |
| Myfortic | 11 | $5,884 | $535 |
| Nexium | 11 | $3,480 | $316 |
| Gengraf | 20 | $3,221 | $161 |
| Creon | 12 | $2,734 | $228 |
| Lactulose | 51 | $2,252 | $44 |
| Cyclosporine Modified | 11 | $2,215 | $201 |
| Calcium Acetate | 12 | $1,794 | $150 |
| Ribavirin | 11 | $1,257 | $114 |
| Midodrine | 12 | $1,213 | $101 |
| Azathioprine | 34 | $1,200 | $35 |
| Amiloride | 11 | $1,112 | $101 |
| Omeprazole | 139 | $1,094 | $8 |
| Spironolactone | 77 | $1,073 | $14 |
| Pantoprazole | 69 | $918 | $13 |
| Prednisone | 90 | $843 | $9 |
| Generlac | 18 | $599 | $33 |
| Fludrocortisone Acetate | 39 | $599 | $15 |
| Propranolol | 31 | $457 | $15 |
| Amlodipine Besylate | 88 | $366 | $4 |
| Furosemide | 72 | $301 | $4 |
| Tamsulosin | 15 | $230 | $15 |
| Levothyroxine | 17 | $204 | $12 |
| Citalopram Hbr | 25 | $181 | $7 |
| Metoprolol | 40 | $137 | $3 |
| Glipizide | 18 | $111 | $6 |
| Trazodone | 15 | $91 | $6 |
| Tramadol | 13 | $58 | $4 |
| Sulfamethoxazole-Trimethoprim | 11 | $55 | $5 |
| Hydrochlorothiazide | 12 | $17 | $1 |
2014: 44 drugs
| Sovaldi | 180 | $5,239,173 | $29,107 |
| Olysio | 101 | $2,330,109 | $23,070 |
| Harvoni | 37 | $1,169,273 | $31,602 |
| Baraclude | 212 | $260,413 | $1,228 |
| Xifaxan | 96 | $130,419 | $1,359 |
| Viread | 111 | $111,272 | $1,002 |
| Tacrolimus | 375 | $78,883 | $210 |
| Procrit | 14 | $48,810 | $3,486 |
| Pegasys Proclick | 14 | $44,008 | $3,143 |
| Ribapak | 44 | $41,524 | $944 |
| Ursodiol | 168 | $31,136 | $185 |
| Entecavir | 26 | $28,481 | $1,095 |
| Atovaquone | 12 | $17,084 | $1,424 |
| Prograf | 39 | $14,331 | $367 |
| Mycophenolate Mofetil | 127 | $8,391 | $66 |
| Ribavirin | 25 | $5,185 | $207 |
| Lamivudine Hbv | 14 | $5,112 | $365 |
| Nexium | 14 | $5,069 | $362 |
| Gengraf | 21 | $3,517 | $167 |
| Ribasphere | 13 | $2,811 | $216 |
| Creon | 12 | $2,444 | $204 |
| Fluconazole | 13 | $1,685 | $130 |
| Generlac | 46 | $1,264 | $27 |
| Fludrocortisone Acetate | 83 | $1,218 | $15 |
| Lactulose | 37 | $1,153 | $31 |
| Amiloride | 13 | $966 | $74 |
| Pantoprazole | 52 | $905 | $17 |
| Omeprazole | 93 | $804 | $9 |
| Spironolactone | 45 | $781 | $17 |
| Azathioprine | 24 | $666 | $28 |
| Prednisone | 56 | $567 | $10 |
| Potassium Chloride | 29 | $460 | $16 |
| Amlodipine Besylate | 80 | $378 | $5 |
| Propranolol | 47 | $295 | $6 |
| Furosemide | 58 | $258 | $4 |
| Sulfamethoxazole-Trimethoprim | 23 | $173 | $8 |
| Tamsulosin | 14 | $159 | $11 |
| Citalopram Hbr | 16 | $141 | $9 |
| Fluticasone Propionate | 13 | $133 | $10 |
| Amitriptyline | 16 | $130 | $8 |
| Metoprolol | 25 | $126 | $5 |
| Lisinopril | 12 | $71 | $6 |
| Famotidine | 13 | $50 | $4 |
| Hydrochlorothiazide | 12 | $31 | $3 |
2013: 33 drugs
| Baraclude | 202 | $207,787 | $1,029 |
| Viread | 87 | $79,317 | $912 |
| Tacrolimus | 241 | $64,863 | $269 |
| Xifaxan | 46 | $61,717 | $1,342 |
| Pegasys Proclick | 11 | $32,987 | $2,999 |
| Myfortic | 17 | $14,841 | $873 |
| Epivir Hbv | 19 | $9,846 | $518 |
| Mycophenolate Mofetil | 105 | $8,975 | $85 |
| Prograf | 23 | $8,714 | $379 |
| Ursodiol | 100 | $8,180 | $82 |
| Nexium | 31 | $6,711 | $216 |
| Ribavirin | 11 | $3,624 | $329 |
| Lamivudine | 13 | $2,971 | $229 |
| Gengraf | 19 | $1,921 | $101 |
| Omeprazole | 108 | $1,235 | $11 |
| Pantoprazole | 37 | $1,136 | $31 |
| Azathioprine | 40 | $1,047 | $26 |
| Spironolactone | 29 | $895 | $31 |
| Fludrocortisone Acetate | 46 | $711 | $15 |
| Generlac | 17 | $650 | $38 |
| Lactulose | 18 | $595 | $33 |
| Lansoprazole | 11 | $594 | $54 |
| Prednisone | 55 | $345 | $6 |
| Amlodipine Besylate | 54 | $328 | $6 |
| Tamsulosin | 21 | $254 | $12 |
| Fluconazole | 11 | $247 | $22 |
| Famotidine | 13 | $218 | $17 |
| Levothyroxine | 14 | $146 | $10 |
| Furosemide | 26 | $133 | $5 |
| Metoprolol | 21 | $126 | $6 |
| Propranolol | 17 | $105 | $6 |
| Sulfamethoxazole-Trimethoprim | 11 | $86 | $8 |
| Hydrochlorothiazide | 12 | $36 | $3 |
Money from drug and device companies
$654 in 2025
| 2025 | 2 | 2 | $625 | $654 |
| 2024 | 2 | 12 | $10,873 | $12,644 |
| 2023 | 3 | 7 | $6,863 | $7,011 |
| 2022 | 1 | 1 | $2,100 | $2,100 |
| 2020 | 1 | 2 | None | $47 |
| 2019 | 1 | 1 | $2,640 | $2,640 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Bausch Health US | None | $625 | 1 payment
|
| Mauna Kea Technologies | None | $29 | 1 payment
|
See all 2 published payments
| Mauna Kea Technologies | Meals · 2025-07-21 | None | $29 |
| Bausch Health US | Consulting · 2025-03-20 | None | $625 |
See earlier years (2024, 2023, 2022, 2020, 2019)
2024: $12,644
| Merck Sharp & Dohme | None | $7,871 | 9 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $4,773 | 3 payments
|
2023: $7,011
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $3,221 | 4 payments
|
| Novo Nordisk | None | $2,713 | 1 payment
|
| Siemens Medical Solutions USA | None | $1,077 | 2 payments
|
2022: $2,100
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $2,100 | 1 payment
|
2020: $47
| Boston Scientific | General - Io Ablation | $47 | 2 payments
|
2019: $2,640
| Intercept Pharmaceuticals | None | $2,640 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Intercept Pharmaceuticals, Inc. · Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due To Nonalcoholic Steatohepatitis (Reverse) · 2023 | Their institution | $55,005 |
| Intercept Pharma Europe Ltd. · Randomized Global Phase 3 Study To Evaluate the Impact on Nash With Fibrosis of Obeticholic Acid Treatment (Regenerate) · 2023 | Their institution | $35,594 |
| Intercept Pharmaceuticals, Inc. · Ocaliva · 2020 | Their institution | $32,208 |
| Intercept Pharmaceuticals, Inc. · 2019 | Their institution | $27,326 |
| Intercept Pharmaceuticals, Inc. · Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due To Nonalcoholic Steatohepatitis (Reverse) · 2022 | Their institution | $25,295 |
| Intercept Pharmaceuticals, Inc. · Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due To Nonalcoholic Steatohepatitis (Reverse) · 2021 | Their institution | $24,258 |
| Intercept Pharma Europe Ltd. · Randomized Global Phase 3 Study To Evaluate the Impact on Nash With Fibrosis of Obeticholic Acid Treatment (Regenerate) · 2024 | Their institution | $22,232 |
| Intercept Pharmaceuticals, Inc. · Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due To Nonalcoholic Steatohepatitis (Reverse) · 2024 | Their institution | $19,155 |
| Intercept Pharmaceuticals, Inc. · Randomized Global Phase 3 Study To Evaluate the Impact on Nash With Fibrosis of Obeticholic Acid Treatment (Regenerate) · 2022 | Their institution | $18,923 |
| Intercept Pharmaceuticals, Inc. · Ocaliva · 2019 | Their institution | $18,891 |
| Intercept Pharmaceuticals, Inc. · 2020 | Their institution | $17,001 |
| Intercept Pharmaceuticals, Inc. · Randomized Global Phase 3 Study To Evaluate the Impact on Nash With Fibrosis of Obeticholic Acid Treatment (Regenerate) · 2021 | Their institution | $13,962 |
| Intercept Pharmaceuticals, Inc. · Randomized Global Phase 3 Study To Evaluate the Impact on Nash With Fibrosis of Obeticholic Acid Treatment (Regenerate) · 2023 | Their institution | $4,503 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 96.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1447351747
- Licence
- CA A60520California A60520: Current · expires 2028-05-31
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A605200
- Taxonomy
- Federal specialty code 207RI0008X (207RI0008X); Federal specialty code 207QB0002X (207QB0002X); Federal specialty code 207RG0100X (207RG0100X); Federal specialty code 207RT0003X (207RT0003X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-09-26
- NPI last updated
- 2026-09-03
- NPI record certified
- 2026-09-03
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1551 Bishop St Ste 510, San Luis Obispo, CA, 93401 · 1255 Las Tablas Rd Ste 201, Templeton, CA, 93465